Status:
TERMINATED
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)
Lead Sponsor:
Eli Lilly and Company
Collaborating Sponsors:
Incyte Corporation
Conditions:
Systemic Lupus Erythematosus
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The reason for this long term study is to see how safe and effective the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE) who have completed the final treatme...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Have completed the final treatment study visit of an originating study, such as study JAHZ (NCT03616912) or Study JAIA (NCT03616964).
Exclusion
Key Trial Info
Start Date :
September 9 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2022
Estimated Enrollment :
1147 Patients enrolled
Trial Details
Trial ID
NCT03843125
Start Date
September 9 2019
End Date
April 1 2022
Last Update
May 16 2023
Active Locations (297)
Enter a location and click search to find clinical trials sorted by distance.
1
Achieve Clinical Research, LLC
Birmingham, Alabama, United States, 35216
2
Arizona Arthritis & Rheumatology Research
Phoenix, Arizona, United States, 85032
3
Arizona Arthritis & Rheumatology Associates, P. C.
Tucson, Arizona, United States, 85704
4
Wallace Rheumatic Studies Center
Beverly Hills, California, United States, 90211